Immunogenicity persistence of hepatitis A vaccines Healive® and Havrix® among children:15 years follow-up and long-term prediction-Reference-Cited by-同舟云学术

Immunogenicity persistence of hepatitis A vaccines Healive® and Havrix® among children:15 years follow-up and long-term prediction

Author:

Wang Xiaoli¹,Xu Wenguo²,Hu Yuansheng³,Yao Hui¹,Xu Li⁴,Ma Minhua⁵,Zhang Ying⁶,Wang Yalong⁷

Affiliation:

1. Beijing Office of Global Health, Beijing Center for Disease Prevention and Control, Beijing, China

2. Center for Disease Control and Prevention of Changzhou City, Changzhou, Jiangsu, China

3. Clinical Research and Development Center, Sinovac Biotech, Beijing, China

4. Quality Assurance Department, Sinovac Biotech, Beijing, China

5. Hepatitis A Department, Sinovac Biotech, Beijing, China

6. QMS General Office, Sinovac Biotech, Beijing, China

7. Emergency Department, Center for Disease Control and Prevention of Changzhou City, Changzhou, Jiangsu, China

Funder

National Key R&D Program of China

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

Reference15 articles.

5. WHO position paper on hepatitis A vaccines – October 2022;WHO;Wkly Epidemiol Rec,2022

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献